AI Terminal
Xspray Pharma
Pre-Annual General Meeting Information • Oct 24, 2023
3129_rns_2023-10-24_48f18312-d573-485e-b70a-58fc2c44cee6.pdf
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
Xspray Pharma's Nomination Committee for the Annual General Meeting 2024
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee's composition for the Annual General Meeting in 2024.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 16 May 2023, consists of:
- Thomas Eldered, appointed by Flerie Invest AB
- Gillis Cullin, appointed by Östersjöstiftelsen
- Johan Gyllenswärd, appointed by Ribbskottet AB
- Jan Särlvik, appointed by AP4
- Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
The Nomination Committee shall, before the Annual General Meeting 2024, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, election of auditors, the determination of fees and matters pertaining thereto.
Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting on May 21, 2024, can do so via e-mail to [email protected] before April 2, 2024.
For further information about the Nomination Committee, please contact: Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB Email: [email protected]
For further information, please contact:
Kerstin Hasselgren Chief Financial Officer Xspray Pharma AB Mob: +46 (0) 70 311 16 83 E-mail: [email protected]
About Xspray Pharma
Xspray Pharma AB (publ) is a pharmaceutical company with numerous product candidates in clinical development, utilizing its innovative, patented HyNap-technology to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology segment often with high drug prices. The company's goal is to become a market leader of enhanced PKIs for cancer treatment. Xspray Pharma's primary drug candidate, Dasynoc (XS004-dasatinib), is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose because of better solubility profile. Its compatibility with proton pump inhibitors (PPIs), commonly co-prescribed to chronic myeloid leukemia patients, provides a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®).
Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com
Attachments
Xspray Pharma's Nomination Committee for the Annual General Meeting 2024